Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 3/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20810903 | 1.00 | LMNA (0.48) | LMNAGPR84FFAR1DNM1TSHR | |
| SCHEMBL30438205 | 0.91 | LMNA (0.52) | LMNAGPR84DNM1TSHRTHRB | |
| SCHEMBL20810791 | 0.82 | LMNA (0.48) | LMNAGPR84FFAR1DNM1TSHR | |
| SCHEMBL24972739 | 0.82 | LMNA (0.48) | LMNAGPR84FFAR1DNM1TSHR | |
| SCHEMBL23031750 | 0.79 | LMNA (0.42) | LMNADNM1TSHROPRM1SPHK1 | |
| SCHEMBL27395686 | 0.79 | LMNA (0.52) | LMNAGPR84TSHRFDPSSPHK1 | |
| SCHEMBL24972697 | 0.78 | LMNA (0.45) | LMNAGPR84FFAR1DNM1TSHR | |
| SCHEMBL22327241 | 0.78 | LMNA (0.45) | LMNAGPR84FFAR1DNM1TSHR | |
| SCHEMBL26068564 | 0.78 | LMNA (0.45) | LMNAGPR84FFAR1DNM1TSHR | |
| SCHEMBL18978505 | 0.78 | LMNA (0.54) | LMNAGPR84FFAR1DNM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | LMNA 467/4885GPR84 3739/4885FFAR1 4747/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | LMNA 467/4885GPR84 3739/4885FFAR1 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.